Inventor

HASMANN MAX

DE13 patents

⚠️ This page may combine multiple inventors who share the name “HASMANN MAX”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

KLINGE CO CHEM PHARM FAB

5 patents

US6451816B1Sep 17, 2002

Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression

KLINGE CO CHEM PHARM FAB62 citations95

US6903118B1Jun 7, 2005

Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides

KLINGE CO CHEM PHARM FAB50 citations91

US6593344B1Jul 15, 2003

Piperadinyl-substituted pyridylalkane, alkene and alkine carboxamides

KLINGE CO CHEM PHARM FAB41 citations91

US6506572B2Jan 14, 2003

Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy

KLINGE CO CHEM PHARM FAB18 citations90

US6444823B1Sep 3, 2002

Pyridyl alkane acid amides as cytostatics and immunosuppressives

KLINGE CO CHEM PHARM FAB8 citations72

HOFFMANN LA ROCHE

2 patents

US9687568B2Jun 27, 2017

Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label

HOFFMANN LA ROCHE14 citations84

US9180185B2Nov 10, 2015

Combination therapy of anti-HER3 antibodies

HOFFMANN LA ROCHE13 citations82

ASTELLAS DEUTSCHLAND GMBH

2 patents

US7320993B1Jan 22, 2008

Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents

ASTELLAS DEUTSCHLAND GMBH10 citations81

US7276524B2Oct 2, 2007

Pyridyl alkane acid amides as cytostatics and immunosuppressives

ASTELLAS DEUTSCHLAND GMBH4 citations60

ASTELLAS PHARMA GMBH

2 patents

US7241745B2Jul 10, 2007

Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives

ASTELLAS PHARMA GMBH1 citations47

US7192967B1Mar 20, 2007

Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents

ASTELLAS PHARMA GMBH1 citations45

HASMANN MAX

1 patent

US8529901B2Sep 10, 2013

Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label

HASMANN MAX19 citations89

FRIESS THOMAS

1 patent

US9090700B2Jul 28, 2015

Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

FRIESS THOMAS13 citations79